Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03672006 · ClinicalTrials.gov registry record · Phase 2

t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection

A Phase 2 study of Central Venous Catheter Thrombosis and Central Venous Catheter Associated Bloodstream Infection, sponsored by Medical College of Wisconsin.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target
1
Study location

NCT03672006 is a Phase 2 study of Central Venous Catheter Thrombosis and Central Venous Catheter Associated Bloodstream Infection that has completed, run by Medical College of Wisconsin. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03672006, a Phase 2 study of Central Venous Catheter Thrombosis and Central Venous Catheter Associated Bloodstream Infection, has completed, sponsored by Medical College of Wisconsin.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this pilot study is to test feasibility of concept, consent and enrollment rates, and mechanics of study designed to assess if intra-catheter dwells of tissue plasminogen activator (t-PA) is effective in decreasing the rate of clinically diagnosed central line associated blood stream infection (CLABSI) or venous thromboembolism (VTE) in central venous catheters (CVC) compared to standard of care heparin dwell.

Interventions

  • DRUG Heparin
  • BIOLOGICAL alteplase (recombinant t-PA)

Study Locations (1)

Wisconsin

  • Children's Hospital of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2019-04-22
Est. Completion 2019-12-15
Phase Phase 2

Sponsor

Medical College of Wisconsin

447 total trials

What the Registry Record Tells You About NCT03672006

The ClinicalTrials.gov registry entry for NCT03672006 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Central Venous Catheter Thrombosis appearing as the primary indexed condition, and to 2 interventions - of which Heparin is the first listed.

NCT03672006 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT03672006 about?

NCT03672006 is a clinical study titled "t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection". The purpose of this pilot study is to test feasibility of concept, consent and enrollment rates, and mechanics of study designed to assess if intra-catheter dwells of tissue plasminogen activator (t-PA) is effective in decreasing the rate of clinically diagnosed central line associated blood stream ...

What is the current status of trial NCT03672006?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2019-04-22. Estimated completion is 2019-12-15.

What conditions does trial NCT03672006 study?

This clinical trial studies the following conditions: Central Venous Catheter Thrombosis, Central Venous Catheter Associated Bloodstream Infection.

What interventions are being tested in trial NCT03672006?

The interventions under investigation include: Heparin (DRUG), alteplase (recombinant t-PA) (BIOLOGICAL).

Who is sponsoring clinical trial NCT03672006?

This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03672006 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.